The Use of First Line Highly Active Anti-Retroviral Therapy (HAART) is not Associated with QTc Prolongation in HIV Patients.

Simple item page
dc.contributor.authorOgunmodede, James Ayodele
dc.contributor.authorKolo, P.M., Katibi, I.A. & Omotoso, A.B.O.
dc.date.accessioned2023-05-21T23:13:53Z
dc.date.available2023-05-21T23:13:53Z
dc.date.issued2017
dc.description.abstractBACKGROUND: HAART has improved survival of HIV patients. Its contribution to the development of new cardiovascular abnormalities has generated much interest. This study aimed at determining the prevalence of QTc prolongation among HIV patients and determining the influence if any of the use of HAART on the QTc and on the risk of having QTc prolongation. Sci.2017;27(6):613. MATERIALS AND METHODS: One hundred and fifty HIV positive subjects comprising 76 HIV positive subjects on HAART (Group A), 74 who were HAART- naïve (Group B), and 150 age and sex-matched healthy controls (Group C) were studied. All subjects had electrocardiography, and QTc duration was calculated. RESULTS: Mean QTc was significantly different among the three groups (P <0.001), highest in Group B > Group A > Group C. Frequency of QTc prolongation was highest in Group B (32%)>, Group A (17.3%)> Group C (4.7%) (P<0.001). Mean QTc was significantly longer among patients with CD4 count <200 cells/mm than among those with >200 cells/mm 0.445 + 0.03secs vs 0.421 + 0.03secs (P<0.001). QTc prolongation was commoner among individuals with CD4 count <200 cells/mm 50% vs 20.5% (P<0.001). On binary logistic regression, none of the HAART medications used by our patients was predictive of the occurrence of QTc prolongation. CONCLUSION: The QTc is longer, and QTc prolongation occurs more frequently in HAART-naïve HIV patients than patients on HAART and healthy controls. None of the HAART medications used by our patients was predictive of the development of QTc prolongation.en_US
dc.identifier.citationEthiopian Journal of Health Sciences 27(6):613-620en_US
dc.identifier.urihttps://uilspace.unilorin.edu.ng/handle/20.500.12484/10665
dc.publisherCollege of Health Sciences, Jimma University Ethiopiaen_US
dc.subjectQTc prolongation, HIV/AIDS, Highly Active AntiRetroviral Therapy (HAART)en_US
dc.titleThe Use of First Line Highly Active Anti-Retroviral Therapy (HAART) is not Associated with QTc Prolongation in HIV Patients.en_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
25. EJHS- The use of first line Highly active AntiRetroviral.pdf
Size:
185.53 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections